Amendment to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Previously presented) A pharmaceutical composition comprising the S-isomer of a metabolite of ketotifen, and having the structure:



where R is H, and pharmaceutically acceptable salts and solvates thereof, together with a pharmaceutically acceptable carrier, said composition being free of sedative side effects and being substantially free of the corresponding R-isomer.

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Previously presented) A method for synthesis of the stereochemically active compounds of the structure:



wherein R is H, being of the R- or S-configuration, comprising the conversion of the corresponding stereochemical isomers of ketotifen into their 1-(2,2,2,-trichloro ethoxycarbonyl) nor-intermediates, followed by Cd/Pb-catalyzed cleavage to the final products S-norketotifen or R-norketotifen.

7. (Currently amended) A method for treating a disease selected from the group consisting of allergic disorders, and ~~inflammatory disorders of the skin, the respiratory tract and the~~

~~gastrointestinal tract~~ dermal disorders, bronchial disorders, pulmonary disorders and gastroenterological disorders, which comprises administering to a mammal in need thereof a therapeutically effective amount of the S-isomer of norketotifen or a pharmaceutically acceptable salt or solvate thereof, substantially free of the corresponding R-isomer, while eliminating the dose-limiting sedative side effects of ketotifen.

8. (Currently amended) The method of claim 7, wherein said ~~inflammatory~~ bronchial or pulmonary disorder ~~of the respiratory tract~~ is selected from the group consisting of chronic obstructive pulmonary disease (COPD), asthma, cough, bronchitis and bronchial hyperreactivity.

9. (Previously presented) The method of claim 7, wherein said allergic disorder is selected from the group consisting of allergic rhinitis, urticaria, and allergic conjunctivitis.

10. (Currently amended) The method of claim 7, wherein said ~~inflammatory~~ dermal disorder ~~of the skin~~ is selected from the group consisting of atopic dermatitis, urticaria, and psoriasis.

11. (Cancelled)

12. (Cancelled)

13. (Previously presented) The method of claim 7, wherein the therapeutically active compound or a pharmaceutically acceptable salt or solvate thereof is administered by inhalation or by nasal, parenteral, topical, dermal, transdermal, rectal, sublingual, conjunctival or oral administration.

14. (Original) The method according to claim 7, wherein the therapeutically active compound or a pharmaceutically acceptable salt or solvate thereof is administered orally.

15. (Original) The method according to claim 7, wherein the therapeutically active compound or a pharmaceutically acceptable salt or solvate thereof is administered orally in an extended release formulation.

16. (cancelled)

17. (cancelled)

18. (Original) The method according to claim 7, wherein the amount of the therapeutically active compound is administered from about 0.5 mg to about 200 mg, one to four times per day.

19. (Original) The method according to claim 7, wherein a solid, semi-solid, liquid, suspension, aerosol or topical or transdermal pharmaceutical composition, comprising a therapeutically effective amount of the therapeutically active compound, or a pharmaceutically acceptable salt or solvate thereof, is administered in combination with a pharmaceutically acceptable carrier or carrier system.

20. (Cancelled)

21. (New) A synthetically produced substantially pure form of the S-isomer of a compound of the structure:



where R is H.